Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of ...